These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28494743)

  • 1. Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.
    Antonuzzo L; Lunghi A; Petreni P; Brugia M; Laffi A; Giommoni E; Mela MM; Mazzoni F; Balestri V; Costanzo FD
    Curr Med Chem; 2017; 24(28):3068-3076. PubMed ID: 28494743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
    Sivolella S; Lumachi F; Stellini E; Favero L
    Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws.
    Ramírez L; López-Pintor RM; Casañas E; Arriba Ld; Hernández G
    Oral Health Prev Dent; 2015; 13(5):385-93. PubMed ID: 25884045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.
    Troeltzsch M; Woodlock T; Kriegelstein S; Steiner T; Messlinger K; Troeltzsch M
    J Can Dent Assoc; 2012; 78():c85. PubMed ID: 22985897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district.
    Ponzetti A; Pinta F; Spadi R; Mecca C; Fanchini L; Zanini M; Ciuffreda L; Racca P
    Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 26350200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
    Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
    Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteonecrosis of the jaws and bevacizumab therapy: a case report.
    Brunamonti Binello P; Bandelloni R; Labanca M; Buffoli B; Rezzani R; Rodella LF
    Int J Immunopathol Pharmacol; 2012; 25(3):789-91. PubMed ID: 23058032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology.
    Fusco V; Santini D; Armento G; Tonini G; Campisi G
    Expert Opin Drug Saf; 2016 Jul; 15(7):925-35. PubMed ID: 27074901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.
    Yarom N; Yahalom R; Shoshani Y; Hamed W; Regev E; Elad S
    Osteoporos Int; 2007 Oct; 18(10):1363-70. PubMed ID: 17598065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bisphosphonate-associated osteonecrosis of the jaw].
    Krauth MT; Fügl A; Gruber R
    Wien Klin Wochenschr; 2008; 120(15-16):467-76. PubMed ID: 18820850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab.
    Pakosch D; Papadimas D; Munding J; Kawa D; Kriwalsky MS
    Oral Maxillofac Surg; 2013 Dec; 17(4):303-6. PubMed ID: 23242941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Antiangiogenic Therapy in the Development of Osteonecrosis of the Jaw.
    Fantasia JE
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):547-53. PubMed ID: 26515736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bisphosphonates and osteonecrosis of the jaws].
    Urade M
    Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab, sunitinib: osteonecrosis of the jaw.
    Prescrire Int; 2011 Jun; 20(117):155. PubMed ID: 21682016
    [No Abstract]   [Full Text] [Related]  

  • 16. Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates.
    Lorusso L; Pieruzzi L; Gabriele M; Nisi M; Viola D; Molinaro E; Bottici V; Elisei R; Agate L
    J Endocrinol Invest; 2021 Dec; 44(12):2557-2566. PubMed ID: 34291429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw.
    Chang J; Hakam AE; McCauley LK
    Curr Osteoporos Rep; 2018 Oct; 16(5):584-595. PubMed ID: 30155844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone.
    Christodoulou C; Pervena A; Klouvas G; Galani E; Falagas ME; Tsakalos G; Visvikis A; Nikolakopoulou A; Acholos V; Karapanagiotidis G; Batziou E; Skarlos DV
    Oncology; 2009; 76(3):209-11. PubMed ID: 19212145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteonecrosis of the jaw and the role of macrophages.
    Pazianas M
    J Natl Cancer Inst; 2011 Feb; 103(3):232-40. PubMed ID: 21189409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.